Listen
AFINITOR
-
Opinions on drugs -
Posted on
Mar 28 2012
- Updated on
Apr 18 2012
Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use in the extension of indication: “treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease”.
-
Clinical Benefit
| Substantial |
The actual benefit of AFINITOR is substantial. |
Clinical Added Value
| minor |
AFINITOR provides a minor IAB (level IV) in terms of efficacy in the therapeutic management of patients with advanced neuroendocrine tumours of pancreatic origin. |
English version
Contact Us
Évaluation des médicaments
